CoChat

Amphetamine Decreases 2C-Adrenoceptor Binding of [11C]ORM-13070: A PET Study in the Primate Brain

Open access
Finnema, S. J., Hughes, Z. A., Haaparanta-Solin, M., Stepanov, V., Nakao, R., Varnas, K., Varrone, A., Arponen, E., Marjamaki, P., Pohjanoksa, K., Vuorilehto, L., Babalola, P. A., Solin, O., Grimwood, S., Sallinen, J., Farde, L., Scheinin, M., Halldin, C. · 2015 · International Journal of Neuropsychopharmacology

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The neurotransmitter norepinephrine has been implicated in psychiatric and neurodegenerative disorders. Examination of synaptic norepinephrine concentrations in the living brain may be possible with positron emission tomography (PET), but has been hampered by the lack of suitable radioligands. METHODS: We explored the use of the novel α2C-adrenoceptor antagonist PET tracer [(11)C]ORM-13070 for measurement of amphetamine-induced changes in synaptic norepinephrine. The effect of amphetamine on [(11)C]ORM-13070 binding was evaluated ex vivo in rat brain sections and in vivo with PET imaging in monkeys. RESULTS: Microdialysis experiments confirmed amphetamine-induced elevations in rat striatal norepinephrine and dopamine concentrations. Regional [(11)C]ORM-13070 receptor binding was high in the striatum and low in the cerebellum. After injection of [(11)C]ORM-13070 in rats, mean striatal specific binding ratios, determined using cerebellum as a reference region, were 1.4±0.3 after vehicle pretreatment and 1.2±0.2 after amphetamine administration (0.3mg/kg, subcutaneous). Injection of [(11)C]ORM-13070 in non-human primates resulted in mean striatal binding potential (BP ND) estimates of 0.65±0.12 at baseline. Intravenous administration of amphetamine (0.5 and 1.0mg/kg, i.v.) reduced BP ND values by 31-50%. Amphetamine (0.3mg/kg, subcutaneous) increased extracellular norepinephrine (by 400%) and dopamine (by 270%) in rat striata. CONCLUSIONS: Together, these results indicate that [(11)C]ORM-13070 may be a useful tool for evaluation of synaptic norepinephrine concentrations in vivo. Future studies are required to further understand a potential contribution of dopamine to the amphetamine-induced effect.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyu081

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Representative whole-hemisphere autoradiograms showing the distribution of [11C]ORM-13070 binding to sagittal sections of a monkey brain (A), coronal sections of a human brain (B), and coronal sections of two rat brains (C). The rat sections were obtained from animals euthanized 30min post [11C]ORM-13070 injection. Amphetamine (‘Amph’, 0.3mg/kg subcutaneous [s.c.], 20min before i.v. injection of [11C]ORM-13070) tended to reduce the specific binding ratios (mean ± standard deviation, n = 5) in the olfactory tubercle (OT) and striatum (STR) of rats (D). In the primate brain sections, specific binding was demonstrated by co-incubation with a 10 µM concentration of the subtype non-selective α2-adrenoceptor antagonist atipamezole. SBR, specific binding ratio.
Figure 1. Representative whole-hemisphere autoradiograms showing the distribution of [11C]ORM-13070 binding to sagittal sections of a monkey brain (A), coronal sections of a human brain (B), and coronal sections of two rat brains (C). The rat sections were obtained from animals euthanized 30min post [11C]ORM-13070 injection. Amphetamine (‘Amph’, 0.3mg/kg subcutaneous [s.c.], 20min before i.v. injection of [11C]ORM-13070) tended to reduce the specific binding ratios (mean ± standard deviation, n = 5) in the olfactory tubercle (OT) and striatum (STR) of rats (D). In the primate brain sections, specific binding was demonstrated by co-incubation with a 10 µM concentration of the subtype non-selective α2-adrenoceptor antagonist atipamezole. SBR, specific binding ratio.CC BY-NC · PubMed Central
Figure 2. Evaluation of the utility of [11C]ORM-13070 as a positron emission tomography (PET) tracer in cynomolgus monkeys. (A) PET summation images represent mean radioactivity levels in time frames of 9–63min after injection of [11C]ORM-13070. (B) Mean regional brain radioactivity in the striatum (■) and cerebellum (▲) during baseline conditions (mean ± standard deviation, n = 9). (C) Correlation between striatal BP ND (simplified reference tissue model [SRTM], 33min) and mean striatal binding potential (BP ND) estimates calculated by SRTM (63min) and interval method (IM) (n = 20). (D) Radiochromatogram of a plasma sample obtained 30min after i.v. injection of [11C]ORM-13070. SUV, standard uptake value.
Figure 2. Evaluation of the utility of [11C]ORM-13070 as a positron emission tomography (PET) tracer in cynomolgus monkeys. (A) PET summation images represent mean radioactivity levels in time frames of 9–63min after injection of [11C]ORM-13070. (B) Mean regional brain radioactivity in the striatum (■) and cerebellum (▲) during baseline conditions (mean ± standard deviation, n = 9). (C) Correlation between striatal BP ND (simplified reference tissue model [SRTM], 33min) and mean striatal binding potential (BP ND) estimates calculated by SRTM (63min) and interval method (IM) (n = 20). (D) Radiochromatogram of a plasma sample obtained 30min after i.v. injection of [11C]ORM-13070. SUV, standard uptake value.CC BY-NC · PubMed Central
Figure 3. (A) Time activity course for regional radioactivity (SUV) in the striatum and cerebellum during baseline and pretreatment with atipamezole (500 µg/kg) before i.v. injection of [11C]ORM-13070 in a representative cynomolgus monkey. (B) Relative decrease in mean striatal binding potential as a function of atipamezole dose and atipamezole concentration in plasma. The lines represent a constrained one-site binding fit.
Figure 3. (A) Time activity course for regional radioactivity (SUV) in the striatum and cerebellum during baseline and pretreatment with atipamezole (500 µg/kg) before i.v. injection of [11C]ORM-13070 in a representative cynomolgus monkey. (B) Relative decrease in mean striatal binding potential as a function of atipamezole dose and atipamezole concentration in plasma. The lines represent a constrained one-site binding fit.CC BY-NC · PubMed Central
Figure 4. (A) Extracellular concentrations of norepinephrine (NE) and dopamine (DA) in the striatum of awake or anesthetized rats. The effects of amphetamine (0.3mg/kg s.c., administered at t = 0) on concentrations of NE (B) and DA (C). The mean effects of amphetamine (Amph; 0.3mg/kg s.c.) and atomoxetine (Atom; 1mg/kg i.p.) on NE and DA in freely-moving rats expressed as percent of basal concentrations (D). Data are means ± standard error of the mean, *p < 0.05. Veh, vehicle.
Figure 4. (A) Extracellular concentrations of norepinephrine (NE) and dopamine (DA) in the striatum of awake or anesthetized rats. The effects of amphetamine (0.3mg/kg s.c., administered at t = 0) on concentrations of NE (B) and DA (C). The mean effects of amphetamine (Amph; 0.3mg/kg s.c.) and atomoxetine (Atom; 1mg/kg i.p.) on NE and DA in freely-moving rats expressed as percent of basal concentrations (D). Data are means ± standard error of the mean, *p < 0.05. Veh, vehicle.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 3

  1. Jakobsen, 2006, Journal of Nuclear Medicine, 47, 2008
  2. Laruelle, 1995, Journal of Nuclear Medicine, 36, 1182
  3. Marasini, 1991, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies, 29, 111

Cited by

See all 17

Metadata

Authors
Finnema, S. J., Hughes, Z. A., Haaparanta-Solin, M., Stepanov, V., Nakao, R., Varnas, K., Varrone, A., Arponen, E., Marjamaki, P., Pohjanoksa, K., Vuorilehto, L., Babalola, P. A., Solin, O., Grimwood, S., Sallinen, J., Farde, L., Scheinin, M., & Halldin, C.
Affiliations
University of Turku (FI)
Corresponding author
  • Scheinin, M.
  • Halldin, C.
Venue
International Journal of Neuropsychopharmacology
Published
2014-12-13
Volume
18
Issue
3
Pages
pyu081-pyu081
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W1758995111
Cited by
17
References
48
Citations by year
2024: 2 · 2023: 1 · 2022: 1 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 3 · 2016: 1 · 2015: 2
FWCI
0.91
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • European Federation of Pharmaceutical Industries and Associations
  • European Commission (FP7/2007, 115008)
  • Innovative Medicines Initiative
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
amphetamine, alpha2C-adrenoceptor, dopamine, striatum, PET radiotracer, microdialysis, non-human primates
MeSH terms
Atomoxetine Hydrochloride, Amphetamine, Central Nervous System Stimulants, Animals, Brain, Dioxanes, Female, Humans, Imidazoles, Macaca fascicularis, Male, Piperazines, Propylamines, Protein Binding, Time Factors, Rats, Sprague-Dawley, Receptors, Adrenergic, alpha-2, Adrenergic Uptake Inhibitors, Radiopharmaceuticals, Positron-Emission Tomography, Rats, Adrenergic alpha-2 Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.